Trials / Recruiting
RecruitingNCT07205315
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Chronic Lymphocytic Leukemia (CLL)
- B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Autoimmune Hemolytic Anemia (AIHA)
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT801 Injection | GT801 Injection |
Timeline
- Start date
- 2025-09-26
- Primary completion
- 2027-11-30
- Completion
- 2028-08-31
- First posted
- 2025-10-03
- Last updated
- 2025-12-26
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07205315. Inclusion in this directory is not an endorsement.